ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).

Breast Cancer

Richard G. Margolese, MD, and Robert W. Carlson, MD

Richard G. Margolese, MD, and Robert W. Carlson, MD, on NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Robert W. Carlson, MD, of the National Comprehensive Cancer Network, and Richard G. Margolese, MD, of McGill University, discuss the improvement in breast cancer–free interval with anastrozole vs tamoxifen in patients with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract LBA500).

Global Cancer Care

Tony Mok, MD, and James O. Armitage, MD

Tony Mok, MD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Asian Perspective

James O. Armitage, MD, of the University of Nebraska Medical Center, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss oncology from an international point of view.

Hematologic Malignancies

Ruben A. Mesa, MD, and James O. Armitage, MD

Ruben A. Mesa, MD, and James O. Armitage, MD, Results of the PERSIST-1 Study on Myelofibrosis

James O. Armitage, MD, of The University of Nebraska Medical Center, and Ruben A. Mesa, MD, of the Mayo Clinic, discuss pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).

Lung Cancer

Palliative Care

Symptom Management

Charles F. von Gunten, MD, PhD

Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care

Charles F. von Gunten, MD, PhD, of OhioHealth Kobacker House discusses the ROMANA 1 and 2 trials on cachexia in NSCLC and a study on olanzapine vs fosaprepitant for the prevention of nausea and vomiting (Abstracts 9500 and 9502).

Jun

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Richard G. Margolese, MD, and Robert W. Carlson, MD, on NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Tony Mok, MD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Asian Perspective

Ruben A. Mesa, MD, and James O. Armitage, MD, Results of the PERSIST-1 Study on Myelofibrosis

Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care

Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer

Teclistamab in Previously Treated Multiple Myeloma

Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma

Sunvozertinib in NSCLC With EGFR Exon 20 Insertion Mutations